Yi An

Dr. Yi An is an Associate Professor of Therapeutic Radiology at Yale School of Medicine, where he serves as Chief of the Genitourinary Radiotherapy Program and Chief of the Spine Radiotherapy Program. He is primarily based at Smilow Cancer Hospital Care Center in New Haven, CT and Trumbull, CT, providing specialized radiation oncology services across multiple cancer types.

• Yale Cancer Center
• Center for Gastrointestinal Cancers
• Central Nervous System Radiotherapy Program
• Head and Neck Cancers Program
• Pituitary Program
• Prostate & Urologic Cancers Program
• Spine Oncology Program

Dr. An received his medical degree from Stanford University School of Medicine (2013) and completed his residency and served as chief resident at Yale School of Medicine (2017-2018). His clinical expertise spans prostate cancer, bladder cancer, brain/spine radiosurgery, and brain cancers, with specialization in modern radiation treatment techniques including intensity-modulated radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery.

His research focuses on optimizing radiation therapy for genitourinary cancers, particularly through the FORMULA-509 clinical trial investigating salvage radiotherapy and hormone therapy after radical prostatectomy. Dr. An's work demonstrates a strong commitment to understanding patient-reported quality of life outcomes alongside clinical efficacy. His publication record shows consistent contributions to the fields of prostate cancer treatment, brain metastases management, and the integration of radiation therapy with novel treatment approaches.

As evidenced by his publication history, Dr. An's research spans multiple domains within radiation oncology, with particular emphasis on clinical trials methodology, quality of life assessment in cancer treatment, and technical innovations in radiation delivery. His work often involves multi-institutional collaborations, reflecting his integration within the broader radiation oncology research community.

Dr. An is actively involved in clinical trials research, including Phase II trials of stereotactic body radiation therapy for oligoprogression on immune checkpoint inhibitors in metastatic renal cell carcinoma, and trials investigating MRI brain surveillance versus prophylactic cranial irradiation in small-cell lung cancer.